

PATIENT

Patient: SAMPLE PATIENT
DOB/Sex:
MR/Chart #:
Accession #:

SPECIMEN

Specimen: 2 BM NA HEP, 1 BM EDTA
Collected: 3/5/2012
Received: 3/6/2012
All Specimens: 2 BM NA HEP, 1 BM EDTA

PHYSICIAN

SAMPLE DOCTOR
Copies:
REPORT DATE: 3/9/2012

CLINICAL HISTORY:

Mantle Cell Lymphoma

INTERPRETATION:

No metaphase cells available for analysis

SUMMARY OBSERVATION:

Cultured bone marrow cells did not demonstrate any fully analyzable metaphase cells precluding cytogenetic analysis. The patient with history of Mantle Cell Lymphoma has been treated therefore, probably compromising mitotic activity in culture.

(X) RECOMMENDATION(S): Repeat chromosome studies as the patient's clinical condition changes. Cytogenetic reevaluation will be helpful in assessing remission or relapse of the malignancy and/or to rule out the presence or absence of the abnormal clone. Progression of malignancy is usually accompanied by further karyotypic evolution.

Electronically signed
3/9/2012 2:52 PM by
Anita Kulharya, Ph.D.
Cytogenetics Director

Dr. Douglas W. Kingma, Laboratory Director

Howard L. Martin, III, M.D., Medical Director

CLIA #: 44D0915029, TN License #: 0000003284

Due to limitation of chromosome morphology and banding in neoplastic cell preparations, presence of subtle clonal chromosomal abnormalities and cryptic translocations, if any, in addition to the results reported from the karyotype analysis cannot be ruled out.

IDC9 Codes: 200.40 CPT Codes: 88237; 88291

OncoMetrix

Poplar Healthcare, PLLC
150 Collins Street, Memphis, TN 38812

(877) 670-HEME (4363)